Rheumatoid Arthritis

Rheumatoid arthritis (RA) is a chronic, systemic inflammatory disorder that may affect many tissues and organs, but principally attacks flexible (synovial) joints. The process involves an inflammatory response of the capsule around the joints (synovium) secondary to swelling (hyperplasia) of synovial cells, excess synovial fluid, and the development of fibrous tissue (pannus) in the synovium. The pathology of the disease process often leads to the destruction of articular cartilage and ankylosis (fusion) of the joints. Rheumatoid arthritis can also produce diffuse inflammation in the lungs, membrane around the heart (pericardium), the membranes of the lung (pleura), and white of the eye (sclera), and also nodular lesions, most common in subcutaneous tissue. Although the cause of rheumatoid arthritis is unknown, autoimmunity plays a pivotal role in both its chronicity and progression, and RA is considered a systemic autoimmune disease.

About 1% of the world's population has rheumatoid arthritis, women three times more often than men. Onset is most frequent between the ages of 40 and 50, but people of any age can be affected. In addition, individuals with the HLA-DR1 or HLA-DR4 serotypes have an increased risk for developing the disorder. It can be a disabling and painful condition, which can lead to substantial loss of functioning and mobility if not adequately treated. It is a clinical diagnosis made on the basis of symptoms, physical exam, radiographs (X-rays) and labs, although the American College of Rheumatology (ACR) and the European League Against Rheumatism (EULAR) publish classification criteria for the purpose of research. Diagnosis and long-term management are typically performed by a rheumatologist, an expert in joint, muscle and bone diseases.

Various treatments are available. Non-pharmacological treatment includes physical therapy, orthoses, occupational therapy and nutritional therapy but these do not stop the progression of joint destruction. Analgesia (painkillers) and anti-inflammatory drugs, including steroids, are used to suppress the symptoms, while disease-modifying antirheumatic drugs (DMARDs) are required to inhibit or halt the underlying immune process and prevent long-term damage. In recent times, the newer group of biologics has increased treatment options. Clinical trials have shown that consumption of fish oil reduces the number of swollen joints for people with rheumatoid arthritis, provides a beneficial anti-inflammatory effect, and provides a protective effect for occlusive cardiovascular disease, for which people with RA are at risk.

The name is based on the term "rheumatic fever", an illness which includes joint pain and is derived from the Greek word ῥεύμα-rheuma (nom.), ῥεύματος-rheumatos (gen.) ("flow, current"). The suffix -oid ("resembling") gives the translation as joint inflammation that resembles rheumatic fever. The first recognized description of rheumatoid arthritis was made in 1800 by Dr. Augustin Jacob Landré-Beauvais (1772–1840) of Paris.

Read more about Rheumatoid Arthritis:  Signs and Symptoms, Causes, Pathophysiology, Management, Prognosis, Epidemiology, History

Other articles related to "rheumatoid arthritis, arthritis":

List Of Bestselling Drugs
... Adalimumab 1,152,261 13.45% Abbott Laboratories Rheumatoid arthritis Dec-2002 Dec-2016 6 Advair Diskus, Seretide Fluticasone + Salmeterol 1,148,611 2.10 ... Mitsubishi Tanabe Pharma Crohn's disease, Rheumatoid arthritis Aug-1998 n/a 9 Copaxone Glatiramer 877,591 9.93% Teva Pharmaceutical Industries, Sanofi-Aventis Multiple sclerosis Dec-1996 ... Celecoxib 492,984 12.77% Pfizer Osteoarthritis and rheumatoid arthritis Dec-1998 May-2014 23 Singulair Montelukast 486,837 -62.20% Merck Co ...
Rheumatoid Arthritis - History - Notable Cases
... He also wrote a book on living with arthritis ... who had to retire from active play because of rheumatoid arthritis ... Dorothy Hodgkin, Nobel prize winning scientist, developed severe deforming rheumatoid arthritis at age 28 ...
Lexicon Pharmaceuticals - Clinical Pipeline - LX2931 For Rheumatoid Arthritis
... under development for the potential treatment of autoimmune diseases such as rheumatoid arthritis ... of LX2931 and its effects on symptoms and signs associated with rheumatoid arthritis. 2 trial is expected to enroll up to 200 patients with rheumatoid arthritis who are also taking methotrexate, a standard therapy ...
Anakinra - Basic Chemical, Pharmacological, and Marketing Data
... administration of clinically relevant doses (1 to 2 mg/kg n = 18) for patients with rheumatoid arthritis ... no unexpected accumulations of anakinra were observed in the plasma samples of rheumatoid arthritis patients ... Orphan Biovitrum AB is the global Market Authorisation Holder for Kineret on the indication adult rheumatoid arthritis ...
Marc Feldmann - Biography
... Kennedy Institute of Rheumatology to study disease mechanism in rheumatoid arthritis, a much more clinically important autoimmune disease, affecting 1 ... attacks and damages the body, leading to disease of various organs, for example joints in rheumatoid arthritis ... cytokines in test-tube models of arthritis (iv), and this provided the rationale for testing TNF blockade in rheumatoid arthritis patients which had failed all existing treatment ...